Oncology

In Europe, there are more clinical trials conducted in oncology than in any other therapeutic area; oncology trials account for approximately 35% of all clinical trials in Europe. As a result, EastHORN has more experience in oncology than in any other therapeutic area.

The indications that EastHORN has been engaged in are:

  • Anaemia – Chemotherapy Induced
  • B-CLL
  • Breast Cancer
  • Cervical Cancer
  • Chemotherapy Induced Neutropenia
  • Chemotherapy Induced Anemia
  • Colorectal Cancer
  • Gall Bladder Cancer
  • Gastric Cancer
  • gCSF in Bone Marrow Transplantation
  • GI Stromal Tumor
  • Glioblastoma
  • Head and Neck Cancer
  • Hepatocelullar Carcinoma
  • High-grade Glioma
  • Leukemia
  • Lymphoma
  • Lymphangioleiomyomatosis
  • Multiple Myeloma
  • Myelodysplastic Syndrome
  • Nausea and Vomiting – Chemotherapy Induced
  • Neutropenia – Chemotherapy Induced
  • Non-Small Cell Lung Cancer
  • Ovarian Cancer
  • Pain Relief in Cancer Patients
  • Pancreatic Cancer
  • Prostate Cancer
  • Rectal Cancer
  • Renal Cell Cancer
  • Small Cell Lung Cancer
  • Solid Tumors
  • Subependymal Giant Cell Astrocytoma and Angiomyolipoma
  • Thyroid Cancer
  • Tumor Lysis Syndrome
  • and others

EastHORN has experience in the following types of cancer treatments and palliative care:

  • Angiogenesis inhibitors
  • Antibodies
  • Taxanes
  • Platinum agents
  • Antiemetics
  • Alkylating agents
  • Retinoids
  • Radiosensitizers
  • Antibodies
  • Vaccines
  • Interleukins
  • Antiestrogens
  • Growth factors